Stocktoria
Pyxis Oncology, Inc. PYXS
Pyxis Oncology, Inc. (PYXS) earns a Piotroski F-score of 2/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $13.9M at a -574.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.557 |
| Retained earnings / assets | -4.842 |
| EBIT / assets | -0.922 |
| Equity / liabilities | 1.401 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| PYXS | Pyxis Oncology, Inc. | 2/9 | -16.86 | — | -14.2% |
| ABUS | Arbutus Biopharma Corp | 3/9 | — | — | — |
| IRD | Opus Genetics, Inc. | 3/9 | -11.42 | — | +29.1% |
| TNXP | Tonix Pharmaceuticals Holding Corp. | 3/9 | -0.37 | — | +29.8% |
| EVMN | Evommune, Inc. | 2/9 | 9.47 | — | — |
| CNTA | Centessa Pharmaceuticals plc | 4/9 | -1.11 | — | — |
| PRLD | Prelude Therapeutics Inc | 3/9 | -17.29 | — | — |
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has an in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
FAQ
Is PYXS financially healthy?
Pyxis Oncology, Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does PYXS pay a dividend?
No, Pyxis Oncology, Inc. does not currently pay a dividend.
How profitable is PYXS?
In FY2025, Pyxis Oncology, Inc. had a net margin of -574.5% and a return on equity of -149.1%.
What is the analyst price target for PYXS?
The average Wall-Street price target for Pyxis Oncology, Inc. is $7.00, about 120.1% above the recent price, from 8 analysts.
Is PYXS a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Pyxis Oncology, Inc.: a Piotroski F-score of 2/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.